A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Wen, Xiaolin ^a   Pickens, Jennifer ^b,c   Mousa, Jarrod J ^b,c   Leser, George P ^d   Lamb, Robert A ^d   Crowe, James E ^b,c   Jardetzky, Theodore S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; EPITOPE MAPPING; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; MOUSE; NONHUMAN; PROTEIN CONFORMATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; METAPNEUMOVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; EPITOPES; METAPNEUMOVIRUS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84971280734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155917     Document Type: Article

References (41)

1. Collins PL, Crowe JE Jr. Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM, editors. Fields Virology. 6 ed: Lippincott Williams & Wilkins; 2013.
2. Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372:39-57. doi: 10.1007/978-3-642-38919-1-2 PMID: 24362683.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352(17):1749-59. doi: 10.1056/NEJMoa043951 PMID: 15858184.
4. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infectious disorders drug targets. 2012; 12(2):92-7. PMID: 22335498.
5. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001; 7 (6):719-24. Epub 2001/06/01. [pii]. PMID: 11385510.
6. Edwards KM, Zhu Y, Griffin MR, Weinberg GA, Hall CB, Szilagyi PG, et al. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368(7):633-43. doi: 10.1056/ NEJMoa1204630 PMID: 23406028; PubMed Central PMCID: PMC3662802.
7. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004; 350(5):443-50. Epub 2004/01/30. [pii]. PMID: 14749452.
8. Fenton C, Scott LJ, Plosker GL. Palivizumab: A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection. Paediatr Drugs. 2004; 6(3):177-97. PMID: 15170364
9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998; 102(3 Pt 1):531-7. PMID: 9738173.
10. Weisman LE. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Curr Opin Mol Ther. 2009; 11(2):208-18. PMID: 19330726.
11. Gill MA, Welliver RC. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin Biol Ther. 2009; 9(10):1335-45. PMID: 19764889. doi: 10.1517/14712590903287499
12. Lamb RA, Parks GD. Paramyxoviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 1. Fifth ed: Wolters Kluwer | Lippincott WIlliams & Wilkins; 2007. p. 1449-96.
13. Jardetzky TS, Lamb RA. Activation of paramyxovirus membrane fusion and virus entry. Curr Opin Virol. 2014; 5:24-33. doi: 10.1016/j.coviro.2014.01.005 PMID: 24530984; PubMed Central PMCID: PMC4028362.
14. Wen X, Krause JC, Leser GP, Cox RG, Lamb RA, Williams JV, et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat Struct Mol Biol. 2012; 19(4):461-3. doi: 10.1038/nsmb.2250 PMID: 22388735; PubMed Central PMCID: PMC3546531.
15. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7. doi: 10. 1126/science.1234914 PMID: 23618766.
16. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of the Respiratory Syncytial Virus Fusion Glycoprotein in the Post-fusion Conformation Reveals Preservation of Neutralizing Epitopes. J Virol. 2011; 85(15):7788-96. Epub 2011/05/27. JVI.00555-11 [pii] doi: 10.1128/JVI.00555-11 PMID: 21613394.
17. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011; 108(23):9619-24. Epub 2011/05/19. 1106536108 [pii] doi: 10.1073/pnas.1106536108 PMID: 21586636.
18. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature. 2006; 439(7072):38-44. PMID: 16397490.
19. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol. 2010; 17(2):248-50. PMID: 20098425. doi: 10.1038/nsmb.1723
20. Hamelin ME, Gagnon C, Prince GA, Kiener P, Suzich J, Ulbrandt N, et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res. 2010; 88(1):31-7. Epub 2010/07/14. S0166-3542(10)00646-7 [pii] doi: 10.1016/j. antiviral.2010.07.001 PMID: 20619294.
21. Ulbrandt ND, Ji H, Patel NK, Barnes AS, Wilson S, Kiener PA, et al. Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J Gen Virol. 2008; 89(Pt 12):3113-8. Epub 2008/11/15. 89/12/3113 [pii] doi: 10.1099/vir.0.2008/005199-0 PMID: 19008400.
22. Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006; 80 (16):7799-806. Epub 2006/07/29. 80/16/7799 [pii] doi: 10.1128/JVI.00318-06 PMID: 16873237.
23. Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, et al. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog. 2015; 11(7):e1005035. doi: 10.1371/journal.ppat.1005035 PMID: 26161532; PubMed Central PMCID: PMC4498696.
24. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013; 501(7467):439-43. doi: 10.1038/ nature12442 PMID: 23955151.
25. Schuster JE, Cox RG, Hastings AK, Boyd KL, Wadia J, Chen Z, et al. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis. 2015; 211(2):216-25. doi: 10.1093/infdis/jiu307 PMID: 24864121; PubMed Central PMCID: PMC4342691.
26. Stewart-Jones GB, Thomas PV, Chen M, Druz A, Joyce MG, Kong WP, et al. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS One. 2015; 10(6): e0128779. doi: 10.1371/journal.pone.0128779 PMID: 26098893; PubMed Central PMCID: PMC4476739.
27. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013; 342(6158):592-8. doi: 10.1126/science.1243283 PMID: 24179220.
28. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol. 2015; 35:30-8. doi: 10.1016/j.coi.2015.04.005 PMID: 26070108; PubMed Central PMCID: PMC4553118.
29. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, et al. Proof of principle for epitopefocused vaccine design. Nature. 2014; 507(7491):201-6. doi: 10.1038/nature12966 PMID: 24499818.
30. McLellan JS, Correia BE, Chen M, Yang Y, Graham BS, Schief WR, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol. 2011; 409(5):853-66. doi: 10.1016/j.jmb.2011.04.044 PMID: 21549714; PubMed Central PMCID: PMC3107930.
31. Luo X, Liu T, Wang Y, Jia H, Zhang Y, Caballero D, et al. An Epitope-Specific Respiratory Syncytial Virus Vaccine based on an Antibody Scaffold. Angew Chem Int Ed Engl. 2015. doi: 10.1002/anie.201507928 PMID: 26434555.
32. Connolly SA, Leser GP, Yin HS, Jardetzky TS, Lamb RA. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc Natl Acad Sci U S A. 2006; 103(47):17903-8. PMID: 17093041.
33. Swanson K, Wen X, Leser GP, Paterson RG, Lamb RA, Jardetzky TS. Structure of the Newcastle disease virus F protein in the post-fusion conformation. Virology. 2010; 402(2):372-9. PMID: 20439109. doi: 10.1016/j.virol.2010.03.050
34. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011; 162(1-2):80-99. doi: 10.1016/j.virusres.2011.09.020 PMID: 21963675; PubMed Central PMCID: PMCPMC3221877.
35. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013; 31 Suppl 2:B209-15. doi: 10.1016/j. vaccine.2012.11.106 PMID: 23598484; PubMed Central PMCID: PMCPMC3919153.
36. Graham BS, Anderson LJ. Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013; 372:391-404. doi: 10.1007/978-3-642-38919-1-20 PMID: 24362701.
37. Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum Vaccin. 2009; 5(9):582-91. PMID: 19556888.
38. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013; 372:83-104. doi: 10.1007/978-3-642-38919-1-4 PMID: 24362685; PubMed Central PMCID: PMC4211642.
39. McLellan JS, Chen M, Chang JS, Yang Y, Kim A, Graham BS, et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol. 2010; 84(23):12236-44. Epub 2010/10/01. JVI.01579-10 [pii] doi: 10.1128/JVI.01579-10 PMID: 20881049.
40. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, Palumbo E, et al. Rational design of a meningococcal antigen inducing broad protective immunity. Science translational medicine. 2011; 3 (91):91ra62. doi: 10.1126/scitranslmed.3002234 PMID: 21753121.
41. Dormitzer PR, Ulmer JB, Rappuoli R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 2008; 26(12):659-67. Epub 2008/11/04. S0167-7799(08)00247-3 [pii] doi: 10.1016/j.tibtech.2008.08.002 PMID: 18977045.